WO2023011616A1 - 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途 - Google Patents

氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途 Download PDF

Info

Publication number
WO2023011616A1
WO2023011616A1 PCT/CN2022/110448 CN2022110448W WO2023011616A1 WO 2023011616 A1 WO2023011616 A1 WO 2023011616A1 CN 2022110448 W CN2022110448 W CN 2022110448W WO 2023011616 A1 WO2023011616 A1 WO 2023011616A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
compound
cancer
formula
pharmaceutical composition
Prior art date
Application number
PCT/CN2022/110448
Other languages
English (en)
French (fr)
Inventor
杨莹
张喜全
王训强
田心
于鼎
Original Assignee
正大天晴药业集团股份有限公司
首药控股(北京)股份有限公司
连云港润众制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 正大天晴药业集团股份有限公司, 首药控股(北京)股份有限公司, 连云港润众制药有限公司 filed Critical 正大天晴药业集团股份有限公司
Priority to CN202280046318.6A priority Critical patent/CN117597129A/zh
Publication of WO2023011616A1 publication Critical patent/WO2023011616A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the application belongs to the field of medicine, and relates to the use of aminopyrazolopyrimidine compounds in treating tumors mediated by TRK kinase.
  • aminopyrazolopyrimidine compounds in treating tumors mediated by TRK kinase.
  • 2-amino-5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[1,5-a ] Use of pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof in the treatment of TRK kinase-mediated tumors.
  • TRK is a family of tyrosine kinases activated by nerve growth factor, including three subtypes, TRKA, TRKB and TRKC, encoded by NTRK1 (neurotrophic receptor tyrosine kinase 1), NTRK2 and NTRK3 genes, respectively.
  • the complete TRK kinase includes three parts: extracellular region, transmembrane region and intracellular region. After the extracellular receptor region of TRK kinase binds to the corresponding ligand, it can cause a change in the kinase configuration and form a dimer.
  • the intracellular kinase region is autophosphorylated to activate its own kinase activity, and further activate the downstream signal transduction.
  • NGF nerve growth factor
  • BDNF derived neurotrophic factor
  • TRKB TRKB
  • NT3 neurotrophic factor 3
  • TRK kinases play important physiological functions in the development of nerves, including the growth and function maintenance of neuronal axons, the occurrence and development of memory, and the protection of neurons from injury and so on.
  • TRK signal transduction pathways Activated TRK signaling proteins have been found in neurocytoma, prostate cancer, and breast cancer.
  • TRK fusion proteins have shown its biological function of promoting tumorigenesis. The earliest TPM3-TRKA fusion protein was found in colon cancer cells, with an incidence of about 1.5% in clinical patients tested.
  • TRK fusion proteins were found in different types of clinical tumor patient samples such as lung cancer, head and neck cancer, breast cancer, thyroid cancer, glioma, etc., such as CD74-NTRK1, MPRIP-NTRK1, QKI-NTRK2, ETV6 -NTRK3, BTB1-NTRK3, etc.
  • These different TRK fusion proteins are in a state of highly activated kinase activity without the need for ligand binding, so they can continuously phosphorylate downstream signaling pathways, induce cell proliferation, and promote the occurrence and development of tumors. Therefore, in recent years, TRK fusion protein has become an effective anti-cancer target and research hotspot.
  • WO2018077246A1 discloses aminopyrazolopyrimidine compounds such as 2-amino-5-((2R,4S)-2-(2,5-difluorophenyl)-4-fluoropyrrolidin-1-yl)pyrazolo[ 1,5-a] Pyrimidine-3-carboxamide (compound of formula I), which has TRK kinase inhibitory activity, can be used for the treatment of diseases mediated by TRK kinase.
  • the application provides a method for treating TRK kinase-mediated tumors, which comprises administering to a subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof
  • the present application provides a method for treating TRK kinase-mediated tumors, which comprises administering to a subject a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • the present application provides the use of the compound of formula I or its pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of a medicament for treating tumors mediated by TRK kinase.
  • the present application also provides a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating TRK kinase-mediated tumors.
  • the present application also provides the use of the compound of formula I of the present application or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for treating tumors mediated by TRK kinase.
  • the present application provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a medicament for treating TRK kinase-mediated tumors, wherein the medicament comprises, with Based on the weight of the compound of formula I, 0.5-25mg of the compound of formula I or its pharmaceutically acceptable salt or its pharmaceutical composition.
  • the compound of formula I of the present application is used as a single active agent.
  • the compound of formula I of the present application or a pharmaceutically acceptable salt thereof is used as a single active agent in a single dose or a daily dose of 0.5-25 mg (based on the weight of the compound of formula I).
  • the compound of formula I of the present application or a pharmaceutically acceptable salt thereof is used in a single dose or a daily dose of 0.5-25 mg (based on the weight of the compound of formula I).
  • the pharmaceutical composition described herein comprises 0.5-25 mg (based on the weight of the compound of formula I) of the compound of formula I or a pharmaceutically acceptable salt thereof as a single active agent.
  • the pharmaceutical composition comprises a compound of formula I or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.
  • the application provides a method for treating TRK kinase-mediated tumors, which comprises daily administration of 0.5-25 mg of a compound of formula I or its pharmaceutically acceptable A salt, or a pharmaceutical composition thereof (based on the weight of the compound of formula I).
  • the present application also provides a kit for treating TRK kinase-mediated tumors, comprising: a pharmaceutical composition containing a compound of formula I or a pharmaceutically acceptable salt thereof as an active ingredient; optionally, Instructions for use of pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a single-dose pharmaceutical composition comprising 0.5-25 mg of the compound of formula I or a pharmaceutically acceptable salt thereof (based on the weight of the compound of formula I) as an active ingredient.
  • the method for treating tumor provided by the application comprises:
  • the subject is a primate, preferably a human.
  • the tumor is mediated by TRKA, and/or TRKB, and/or TRKC.
  • the tumor is mediated by wild-type (non-mutated) or mutated TRK. In some embodiments, the tumor is mediated by wild-type (non-mutated) or mutant TRKA, and/or TRKB, and/or TRKC.
  • the tumor is mediated by a mutant TRK comprising G667C. In some embodiments, the tumor is mediated by a mutant TRKA comprising G667C, and/or TRKB, and/or TRKC.
  • the mutant is selected from TRKA G667C .
  • the tumor is selected from tumors with an NTRK fusion gene. In some embodiments, the tumor is selected from tumors with a non-mutated or mutated NTRK fusion gene. In some embodiments, the NTRK fusion gene is selected from non-mutant or mutant NTRK1 fusion gene, and/or NTRK2 fusion gene, and/or NTRK3 fusion gene. In some embodiments, the NTRK fusion gene is selected from non-mutated NTRK1 fusion gene, and/or NTRK2 fusion gene, and/or NTRK3 fusion gene.
  • the NTRK fusion gene is selected from an NTRK1 fusion gene, an NTRK2 fusion gene, an NTRK3 fusion gene, or a G667C mutant NTRK1 fusion gene.
  • the NTRK fusion gene may be TPM3-NTRK1, and/or ETV6-NTRK3 and/or LMNA-NTRK3 fusion gene.
  • the NTRK fusion gene can be an ETV6-NTRK3 fusion gene.
  • the NTRK fusion gene can be a LMNA-NTRK3 fusion gene.
  • the NTRK fusion gene may be a TPM3-NTRK1 fusion gene.
  • the tumor is selected from tumors with a TRK fusion protein.
  • the TRK kinase-mediated tumor is selected from tumors with non-mutated or mutated TRK fusion proteins.
  • the TRK kinase-mediated tumor is selected from tumors with non-mutated TRK fusion proteins.
  • the TRK fusion protein is selected from non-mutant or mutant TRKA fusion protein, and/or TRKB fusion protein, and/or TRKC fusion protein.
  • the TRK fusion protein is selected from non-mutant TRKA fusion protein, and/or TRKB fusion protein, and/or TRKC fusion protein.
  • the TRK fusion protein is selected from a TRKA fusion protein, a TRKB fusion protein, a TRKC fusion protein, or a G667C mutant TRKA fusion protein.
  • the method for treating tumor provided by the application comprises:
  • the NTRK fusion gene is selected from non-mutated or mutant NTRK fusion genes. In some embodiments, the NTRK fusion gene is selected from non-mutated NTRK fusion genes. In some embodiments, the NTRK fusion gene is selected from an NTRK1 fusion gene, an NTRK2 fusion gene, and/or an NTRK3 fusion gene. In some embodiments, the NTRK fusion gene is selected from non-mutant NTRK1 fusion gene, NTRK2 fusion gene, and/or NTRK3 fusion gene.
  • the NTRK fusion gene may be a TPM3-NTRK1, and/or ETV6-NTRK3, and/or LMNA-NTRK3 fusion gene. In some embodiments, the NTRK fusion gene can be an ETV6-NTRK3 fusion gene. In some embodiments, the NTRK fusion gene can be a LMNA-NTRK3 fusion gene. In some embodiments, the NTRK fusion gene may be a TPM3-NTRK1 fusion gene.
  • the mutant NTRK fusion gene is selected from NTRK1 G667C .
  • the TRK fusion protein is selected from wild-type (ie non-mutated) or mutant TRK fusion protein. In some embodiments, the TRK fusion protein is selected from TRKA fusion protein, TRKB fusion protein, and/or TRKC fusion protein.
  • the NTRK gene expresses a TRK fusion protein in the tumor.
  • the NTRK gene in the tumor, can express wild-type (ie, non-mutated) or mutant TRK fusion protein.
  • the NTRK1 fusion gene expresses a TRKA fusion protein in the tumor.
  • the G667C mutant NTRK1 fusion gene in the tumor, can express the G667C mutant TRKA fusion protein.
  • the NTRK2 fusion gene expresses a TRKB fusion protein in the tumor.
  • the NTRK3 fusion gene expresses a TRKC fusion protein in the tumor.
  • the NTRK1 fusion gene in the tumor, can express a TRKA fusion protein; the G667C mutant NTRK1 fusion gene can express a G667C mutant TRKA fusion protein; and/or the NTRK2 fusion gene can express a TRKB fusion protein; and /or NTRK3 fusion gene can express TRKC fusion protein.
  • the fusion gene described in the present application may contain a point mutation of NTRK gene or not contain a point mutation of NTRK gene. In some embodiments, the fusion gene described herein may contain a point mutation in the NTRK gene. In some embodiments, the fusion gene described in this application may not contain NTRK gene point mutation.
  • a tumor described herein may be from a patient carrying an NTRK1, NTRK2, or NTRK3 gene fusion without a point mutation in the NTRK gene.
  • a tumor described herein may be from a patient who has previously been treated with a TRK inhibitor.
  • the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 0.0001 to 20 mg/kg weight (calculated by the weight of the compound of formula I) per administration.
  • the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 0.5-25 mg or 5-25 mg (calculated by the weight of the compound of formula I) per administration. In some embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 0.5-20 mg (calculated by the weight of the compound of formula I) for each administration. In some embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 0.5-15 mg (calculated by the weight of the compound of formula I) for each administration.
  • the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 0.5-10 mg (calculated by the weight of the compound of formula I) for each administration. In some embodiments, the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 5-10 mg (calculated by the weight of the compound of formula I) for each administration.
  • the daily dose of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof (based on the weight of the compound of formula I) is selected from 0.5-25 mg or 5-25 mg.
  • the daily dose (by weight of the compound of formula I) of the compound of formula I or its pharmaceutically acceptable salt or pharmaceutical composition thereof is selected from 0.5 mg, or 1 mg, or 2 mg, or 3 mg, or 4 mg , or 5mg, or 6mg, or 7mg, or 8mg, or 9mg, or 10mg, or 11mg, or 12mg, or 13mg, or 14mg, or 15mg, or 16mg, or 17mg, or 18mg, or 19mg, or 20mg, or 21 mg, or 22 mg, or 23 mg, or 24 mg, or 25 mg, or the range formed by any of the above values.
  • the daily dose (based on the weight of the compound of formula I) of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is selected from 0.5 mg-20 mg. In some schemes, the daily dose (based on the weight of the compound of formula I) of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is selected from 0.5 mg-15 mg. In some schemes, the daily dose (based on the weight of the compound of formula I) of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is selected from 0.5 mg-10 mg. In some schemes, the daily dose (based on the weight of the compound of formula I) of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is selected from 5 mg-10 mg.
  • the administration frequency of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof may be 3 times a day, 2 times a day, 1 time a day, 1 time every two days, Once every three days, once every four days, once every five days, once every six days, three times a week, twice a week, once a week, once every two weeks, or once every three weeks Second-rate.
  • the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof may be administered once a day.
  • the administration cycle of the compound of formula I or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof is 1-6 cycles. In some embodiments, the administration cycle of the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is 1, 2, 3, 4, 5, 6 cycles or the range formed by any value above.
  • 15-32 days is used as a dosing cycle, for example, 15-28 days, 15-21 days, 21-28 days, 21-32 days, 28-32 days, 15 days, 16 days days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, or 32 days For 1 dosing cycle. In some embodiments, 28 days or 32 days are used as one administration cycle. In some embodiments, 28-32 days is taken as one administration cycle.
  • administering an effective amount of the compound of formula I of the present application, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a subject is continuous administration.
  • the compound of formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof is administered in single or multiple doses.
  • the subject is selected from subjects with advanced malignant solid tumors diagnosed pathologically and/or cytologically, and/or subjects who lack conventional effective treatment methods or fail or relapse after conventional treatment. tester.
  • the subject is selected from subjects who have not previously received treatment with a TRK inhibitor.
  • the methods provided herein include performing morphological diagnosis, or molecular testing, or a combination of both before administering the compound of formula I or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
  • the methods provided herein comprise assaying a tumor sample obtained from a subject to determine that the subject has a disorder of NTRK gene, TRK protein, or expression or level thereof.
  • the methods provided herein include assaying a tumor sample obtained from a subject to determine that the subject has an NTRK fusion gene or/and a TRK fusion protein.
  • the assay method is selected from one or more of the following methods: denaturing gradient gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE), temperature gradient capillary electrophoresis, single-strand conformation multiple morphological assays, molecular beacon assays, kinetic hybridization assays, PCR-based assays, or denaturing high-performance liquid chromatography.
  • DGGE denaturing gradient gel electrophoresis
  • TGGE temperature gradient gel electrophoresis
  • TGGE temperature gradient capillary electrophoresis
  • single-strand conformation multiple morphological assays single-strand conformation multiple morphological assays
  • molecular beacon assays kinetic hybridization assays
  • PCR-based assays or denaturing high-performance liquid chromatography.
  • the aforementioned tumor is selected from solid tumors.
  • the aforementioned tumor is selected from advanced malignant solid tumors.
  • the aforementioned tumor is selected from adult advanced malignant solid tumors.
  • the aforementioned tumor is selected from glioma, central nervous system tumor, sarcoma, peripheral primitive neuroectodermal tumor, Wilms tumor, lung cancer, thyroid cancer, colorectal cancer, salivary gland cancer, biliary tract cancer, brain cancer , breast cancer, breast ductal carcinoma, head and neck cancer, cell carcinoma, pancreatic cancer, male and female reproductive system tumors, kidney cancer, bile duct cancer, gastric cancer, bronchial cancer, chest cancer, neuroendocrine tumor, lymphoma or melanoma.
  • the aforementioned tumor is selected from soft tissue sarcoma, salivary adenoma, thyroid cancer, lung cancer, melanoma, colorectal cancer, gastric cancer, stromal tumor, cholangiocarcinoma, breast cancer, or pancreatic cancer.
  • the tumor is selected from breast cancer (eg, breast ductal carcinoma, such as invasive breast ductal carcinoma), lung cancer (eg, lung adenocarcinoma), thyroid cancer, or colon cancer (eg, colon adenocarcinoma).
  • breast cancer eg, breast ductal carcinoma, such as invasive breast ductal carcinoma
  • lung cancer eg, lung adenocarcinoma
  • thyroid cancer e.g, adenocarcinoma
  • colon cancer eg, colon adenocarcinoma
  • the aforementioned tumor is selected from adenocarcinoma or thyroid carcinoma.
  • the adenocarcinoma is selected from, eg, ductal carcinoma, breast cancer (eg, ductal carcinoma or invasive ductal carcinoma), lung adenocarcinoma, or colon adenocarcinoma.
  • the tumor is selected from patients with advanced malignant solid tumors clearly diagnosed by pathology and/or cytology; further, it is optionally selected from tumors that lack conventional effective treatment methods or fail or relapse after conventional treatment patient.
  • the tumor is selected from tumor patients with or without prior treatment. In some embodiments, the tumor is selected from patients with previously treated tumors.
  • the tumor is selected from previous surgery, epirubicin, cyclophosphamide, paclitaxel (such as docetaxel), pemetrexed, platinum (such as carboplatin, cisplatin), Tumor patients treated with one or more of anlotinib, radiotherapy or etoposide.
  • epirubicin such as docetaxel
  • paclitaxel such as docetaxel
  • pemetrexed platinum
  • platinum such as carboplatin, cisplatin
  • the tumor is selected from ductal carcinoma, breast cancer (eg, breast ductal carcinoma, such as invasive breast ductal carcinoma), lung cancer (eg, lung adenocarcinoma), thyroid cancer, or colon cancer (eg, colon adenocarcinoma).
  • breast cancer eg, breast ductal carcinoma, such as invasive breast ductal carcinoma
  • lung cancer eg, lung adenocarcinoma
  • thyroid cancer eg, or colon cancer (eg, colon adenocarcinoma).
  • colon cancer eg, colon adenocarcinoma
  • the aforementioned tumor is selected from adenocarcinoma or thyroid carcinoma.
  • the adenocarcinoma is selected from, eg, ductal carcinoma, breast cancer (eg, ductal carcinoma or invasive ductal carcinoma), lung adenocarcinoma, or colon adenocarcinoma.
  • the tumor is selected from tumor patients who have previously received surgical treatment, and/or epirubicin+cyclophosphamide, and/or paclitaxel (such as docetaxel).
  • the tumor is selected from breast cancer patients who have previously received surgical treatment, and/or epirubicin+cyclophosphamide, and/or paclitaxel (such as docetaxel).
  • the tumor is selected from breast ductal carcinoma previously treated with surgery, and/or epirubicin+cyclophosphamide, and/or paclitaxel (eg, docetaxel).
  • the tumor is selected from invasive ductal carcinoma of the breast that has previously been treated with surgery, and/or epirubicin + cyclophosphamide, and/or paclitaxel (eg, docetaxel).
  • the tumor is from a previous modified radical mastectomy (surgery); optionally, further treated with epirubicin + cyclophosphamide; optionally, further treated with paclitaxel (such as doxyl Paclitaxel) treated breast cancer (such as breast ductal carcinoma or invasive breast ductal carcinoma) patients.
  • paclitaxel such as doxyl Paclitaxel
  • breast cancer such as breast ductal carcinoma or invasive breast ductal carcinoma
  • the tumor is selected from tumor patients who have previously received pemetrexed + platinum (such as carboplatin, cisplatin), and/or pemetrexed + anlotinib.
  • the tumor is from a lung cancer patient who has previously received pemetrexed + platinum (such as carboplatin, cisplatin), and/or pemetrexed + anlotinib.
  • the tumor is selected from lung adenocarcinoma patients who have previously received pemetrexed + platinum (eg, carboplatin, cisplatin), and/or pemetrexed + anlotinib.
  • the tumor is from a patient with lung cancer (such as lung adenocarcinoma) who has previously received pemetrexed + carboplatin therapy, optionally further received pemetrexed + anlotinib therapy.
  • lung cancer such as lung adenocarcinoma
  • the tumor is selected from tumor patients who have previously received surgery and/or radiation therapy. In some embodiments, the tumor is from a patient with thyroid cancer who has previously undergone surgery, and/or radiation therapy.
  • the tumor is from a patient with thyroid cancer who has previously undergone radical mastectomy (surgery); optionally, the surgery is selected from the group consisting of lesion thyroidectomy, functional neck dissection, total thyroidectomy One or more of surgery, mediastinal lymph node dissection, and fascioplasty.
  • the tumor is from a thyroid cancer patient who has further received thyroid radiation therapy.
  • the tumor is from a tumor patient who has previously received etoposide and/or platinum (eg, carboplatin, cisplatin) therapy.
  • the tumor is from a colon cancer patient previously treated with etoposide, and/or platinum (eg, carboplatin, cisplatin).
  • the tumor is from a patient with colon adenocarcinoma who has previously been treated with etoposide, and/or platinum (eg, carboplatin, cisplatin).
  • the tumor is from a patient with colon cancer (eg, colon adenocarcinoma) who has previously received etoposide treatment, optionally, further treatment with platinum (eg, carboplatin, cisplatin).
  • colon cancer eg, colon adenocarcinoma
  • platinum eg, carboplatin, cisplatin
  • the compound of formula I in the present application can be administered in the form of its free base, and can also be administered in the form of its pharmaceutically acceptable salt, hydrate and prodrug, and the prodrug can be converted into the free base form of the compound of formula I in vivo.
  • the pharmaceutical composition of the compound of formula I or a pharmaceutically acceptable salt thereof is selected from solid pharmaceutical compositions, preferably tablets or capsules.
  • the compound of formula I or a pharmaceutically acceptable salt thereof is in the form of a pharmaceutical composition, wherein, based on the weight of the compound of formula I, the pharmaceutical composition is a pharmaceutical composition with a single dose of 0.5 mg-25 mg , preferably from a single dose of 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg , 22mg, 23mg, 24mg, 25mg or the pharmaceutical composition of the range formed by any of the above-mentioned values.
  • the pharmaceutical composition of the present application is administered orally.
  • each pharmaceutical composition of the present application is a solid pharmaceutical composition.
  • the preparation form of the solid pharmaceutical composition of the present application is a tablet.
  • TRKA TRKB and TRKC, it is encoded by the genes NTRK1, NTRK2 and NTRK3, respectively.
  • administration refers to the physical introduction of a therapeutic agent or a composition comprising a therapeutic agent to a subject using any of a variety of methods and delivery systems known to those skilled in the art.
  • administration or “administration” or “administration” are used interchangeably herein.
  • treatment generally refers to obtaining a desired pharmacological and/or physiological effect.
  • the effect may be therapeutic in terms of partial or complete stabilization or cure of the disease and/or side effects due to the disease.
  • treatment encompasses any treatment of a disease in a patient, including: (a) inhibiting the symptoms of the disease, ie arresting its development; or (b) relieving the symptoms of the disease, ie causing regression of the disease or symptoms.
  • the term "effective amount” means (i) treating or preventing a particular disease, condition or disorder, (ii) alleviating, ameliorating or eliminating one or more symptoms of a particular disease, condition or disorder, or (iii) preventing or delaying the The amount of a compound of the application for the onset of one or more symptoms of a particular disease, condition or disorder described in .
  • the amount of a compound of the present application that constitutes a “therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by a person skilled in the art according to its own knowledge and this disclosure.
  • subject refers to an animal, preferably a mammal, preferably a primate, including humans and non-human primates (such as apes, monkeys, orangutans and chimpanzees, such as cynomolgus monkeys, spider monkeys and macaques, such as rhesus monkeys), most preferably humans.
  • the subject has experienced and/or exhibited at least one symptom of the disease or condition to be treated and/or prevented.
  • the term "individual” may be a mammal, preferably a primate, most preferably a human.
  • the compound of formula I or a pharmaceutically acceptable salt thereof may be administered by any suitable route and method, such as orally or parenterally (eg, intravenously).
  • pharmaceutical composition refers to a mixture of one or more compounds of the present application or a pharmaceutical combination or salt thereof and pharmaceutically acceptable auxiliary materials.
  • the purpose of the pharmaceutical composition is to facilitate administration of a compound of the present application, or a pharmaceutical combination thereof, to a subject.
  • pharmaceutically acceptable excipients refers to those excipients that have no obvious stimulating effect on the organism and will not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and/or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water and the like.
  • the pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid preparations such as tablets, pills, capsules and the like.
  • the pharmaceutical composition of the present application can be produced by methods well known in the art, such as conventional mixing methods, dissolving methods, granulating methods, dragee-making methods, pulverizing methods, emulsifying methods, freeze-drying methods and the like.
  • pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without excessive Toxicity, irritation, allergic reaction or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • Solid oral pharmaceutical compositions can be prepared by conventional mixing, filling or tabletting methods. It can be obtained, for example, by mixing the active compound with solid excipients, optionally milling the resulting mixture, adding other suitable excipients if desired, and processing the mixture into granules to obtain tablets or the core of a capsule or dragee.
  • suitable auxiliary materials include but are not limited to: binders, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, etc.
  • pharmaceutically acceptable salt or “pharmaceutically acceptable salt” refers to a salt of a compound of the present application that falls within the definition of "pharmaceutically acceptable”.
  • single dose refers to the smallest packaging unit containing a certain amount of medicine.
  • a box of medicine has seven capsules, and each capsule is a single dose; or each bottle of injection is a single dose.
  • multiple dose consists of a number of single doses.
  • the pharmaceutical combination of the present application can be formulated as a pharmaceutical composition suitable for single or multiple administrations. In one embodiment, the pharmaceutical combination of the present application can be a single-dose or multi-dose pharmaceutical composition.
  • ORR Objective Response Rate
  • DCR disease control rate
  • progression-free survival the time from the first medication to disease progression (PD) or death before PD; if there is no PD or death before PD, the date of the last imaging assessment is used as the cut-off date.
  • Term “Duration of Response (DOR)” In subjects with CR or PR, the time between when the tumor was first assessed as CR or PR and death before PD or PD; if the subjects with CR or PR did not develop PD or died before PD, the date of the last imaging assessment was used as the cut-off date.
  • AE Advanced Clinical Event
  • NCI-CTC AE v5.0 Common Toxic Reaction Criteria
  • Moderate Significantly affects the patient's daily life.
  • OS refers to the overall survival time of cancer patients.
  • DFS refers to the disease-free survival period of cancer patients.
  • TTP refers to the time to disease progression of a tumor patient.
  • the treatment plan of the present application has a good curative effect on the treatment of TRK-mediated tumors.
  • the compound of formula I of the present application or pharmaceutically acceptable salt thereof, or its pharmaceutical composition is at least in survival curative effect evaluation (for example OS, median survival period); In tumor response curative effect evaluation (for example DFS, median DFS, PFS, TTP, ORR, DCR, DOR) at least one aspect has an excellent effect.
  • survival curative effect evaluation for example DFS, median DFS, PFS, TTP, ORR, DCR, DOR
  • tumor response curative effect evaluation for example DFS, median DFS, PFS, TTP, ORR, DCR, DOR
  • the compound of formula I of the present application or its pharmaceutically acceptable salt, or its pharmaceutical composition has a low effective dose, good patient tolerance, few side effects, few adverse events, and good patient prognosis. It shows that the compound of formula I of the present application, its pharmaceutically acceptable salt, or its pharmaceutical composition has good medicinal value.
  • the compound of formula (I) can be prepared by referring to the method disclosed in Example 36 of WO2018077246.
  • the SRB method was used to evaluate the inhibitory effect of the compound of formula I on the proliferation ability of human colon cancer cell KM12 in vitro.
  • the cells were seeded in a 96-well plate, and after overnight adherent growth, the compound of formula I was administered at a concentration of 0.0016-16000 nM. After 72 hours of action, the inhibitory effect of the test drug on the proliferation ability of the cell line was detected by the SRB method.
  • test results show that the compound of formula I inhibits the proliferation of KM12 cells in a concentration-dependent manner. See Table 1 for specific values.
  • KM12 cells were cultured in 10% fetal bovine serum, RPMI-1640, and DMEM culture medium in a 37°C, 5% CO 2 incubator. Give the compound of formula I at a concentration (4, 8, 16nM) to treat the cells for 24h and 48h, digest and collect the cells, lyse and prepare protein samples, and detect the expression levels of proteins TRK, PLC ⁇ 1, AKT and Erk by Western Blot.
  • Embodiment 3 experiment in vivo
  • SPF grade female nude mice (source: Nanjing Jicui Yaokang Biotechnology Co., Ltd.) were injected with 5 ⁇ 10 6 human colon cancer KM12 cells under the armpit.
  • the animals are randomly divided into groups according to the tumor volumes and administered.
  • the test animals were intragastrically administered with the compound of formula I at the corresponding concentration according to the administration volume of 10 mL/kg, once a day, and the administration periods were 15 days and 21 days respectively.
  • the tumor volume was weighed and measured twice a week, and the body weight was weighed on the 16th day. After the tumor size was measured, the mice were sacrificed to take the tumor mass and weighed, and the relative tumor volume (RTV), relative tumor proliferation rate (T/C) and Tumor inhibition percentage (IR), and statistical analysis by T-test.
  • RVTV relative tumor volume
  • T/C relative tumor proliferation rate
  • IR Tumor inhibition percentage
  • T/C relative tumor proliferation rate
  • IR tumor inhibition percentage
  • Embodiment 4 clinical trials
  • Compound of formula I strength 0.5mg, 2.5mg, 5mg and 10mg, tablet.
  • NTRK1, NTRK2 or NTRK3 gene fusions are preferentially included;
  • the age is 18-75 years old; ECOG physical status: 0-1 points; the expected survival time is more than 3 months;
  • the compound tablet of formula I, qd is administered under fasting conditions (not taking food within one hour after administration), and the time of each administration should be roughly similar.
  • Indicators include ORR, DCR, PFS, DOR, SD, PR, CR, etc.
  • the curative effect evaluation reached PR and above in C1 (i.e., the first administration cycle), and the tumors of the patients were well controlled after normal administration.
  • the treatment regimens of the present disclosure were found to have clinical benefit.
  • each medication cycle is 28-32 days, for example, C16 means 16 cycles of medication, each cycle is 28-32 days.
  • b represents the best curative effect that has been monitored so far, and the reduction degree of the sum of target lesion diameters compared with the baseline level (the sum of target lesion diameters in stage C0).

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

属于医药领域，涉及氨基吡唑并嘧啶化合物在治疗TRK激酶介导的肿瘤中的用途。具体而言，涉及2-氨基-5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-甲酰胺或其药学上可接受的盐在治疗TRK激酶介导的肿瘤中的用途。

Description

氨基吡唑并嘧啶化合物在治疗TRK激酶介导的肿瘤中的用途
相关申请的引用
本公开要求于2021年08月06日向中华人民共和国国家知识产权局提交的第202110900355.6号中国专利申请的优先权和权益，在此将其全部内容以援引的方式整体并入文本中。
技术领域
本申请属于医药领域，涉及氨基吡唑并嘧啶化合物在治疗TRK激酶介导的肿瘤中的用途。具体而言，涉及2-氨基-5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-甲酰胺或其药学上可接受的盐在治疗TRK激酶介导的肿瘤中的用途。
背景技术
TRK是一类神经生长因子激活的酪氨酸激酶家族，包括TRKA、TRKB和TRKC 3个亚型，分别由NTRK1(neurotrophic receptor tyrosine kinase 1)、NTRK2和NTRK3基因编码。完整的TRK激酶包括胞外区、跨膜区和胞内区三个部分。TRK激酶的胞外受体区与相应的配体结合之后，能够引起激酶构型变化，形成二聚体，胞内激酶区发生自体磷酸化从而激活自身的激酶活性，进而进一步激活下游的信号转导通路(如MAPK，AKT，PKC等)，产生相应的生物学功能；其中，NGF(神经生长因子)结合TRKA，BDNF(衍生的神经营养因子)结合TRKB，NT3(神经营养因子3)结合TRKC。
TRK激酶在神经的发育过程中发挥重要的生理功能，包括神经元轴突的生长与功能维持、记忆的发生发展以及保护神经元免受伤害等等。同时，大量的研究表明TRK信号转导通路的活化与肿瘤的发生发展也有很强的相关性，在神经细胞瘤、前列腺癌、乳腺癌等中都发现了活化的TRK信号蛋白。近几年来多种TRK融合蛋白的发现，更显示了其促进肿瘤发生的生物学功能。最早的TPM3-TRKA融合蛋白是在结肠癌细胞中发现的，在检测的临床病人中约有1.5％的发生率。后来在不同类型的临床肿瘤病人样本如肺癌、头颈癌、乳腺癌、甲状腺癌、神经胶质瘤等中发现了不同类型的TRK融合蛋白，如CD74-NTRK1、MPRIP-NTRK1、QKI-NTRK2、ETV6-NTRK3、BTB1-NTRK3等。这些不同的TRK融合蛋白在不需要配体结合的情况下，自身处于高度活化的激酶活性状态，因而能够持续性地磷酸化下游的信号途径，诱导细胞增殖，促进肿瘤的发生、发展。因此，近几年来，TRK融合蛋白已经成为一个有效的抗癌靶点和研究热点。
WO2018077246A1公开了氨基吡唑并嘧啶化合物例如2-氨基-5-((2R,4S)-2-(2,5-二氟苯基)-4-氟吡咯烷-1-基)吡唑并[1,5-a]嘧啶-3-甲酰胺(式I化合物)，其具有TRK激酶抑制活性，可用于治疗TRK激酶介导的疾病。
发明内容
一方面，本申请提供治疗TRK激酶介导的肿瘤的方法，其包括向受试者施用有效量的式I化合物或其可药用盐、或其药物组合物
Figure PCTCN2022110448-appb-000001
在一些实施方案中，本申请提供治疗TRK激酶介导的肿瘤的方法，其包括向受试者施用治疗有效量的式I化合物或其可药用盐、或其药物组合物。
另一方面，本申请提供了式I化合物或其可药用盐、或其药物组合物在制备用于治疗TRK激酶介导的肿瘤的药物中的用途。本申请还提供用于治疗TRK激酶介导的肿瘤的式I化合物或其可药用盐、或其药物组合物。本申请还提供本申请的式I化合物或其可药用盐、或其药物组合物用于治疗TRK激酶介导的肿瘤的用途。
在一些实施方案中，本申请提供了式I化合物或其可药用盐、或其药物组合物在制备用于治疗TRK激酶介导的肿瘤的药物中的用途，其中，所述药物包含，以式I化合物重量计，0.5-25mg的式I化合物或其可药用盐或其药物组合物。
在一些实施方案中，本申请的式I化合物、或其可药用盐是作为单一活性剂使用。
在一些实施方案中，本申请的式I化合物或其可药用盐以单剂量或每日剂量0.5-25mg(以式I化合物重量计)作为单一活性剂使用。
在一些实施方案中，本申请的式I化合物或其可药用盐以单剂量或每日剂量0.5-25mg(以式I化合物重量计)使用。
在一些实施方案中，本申请所述药物组合物包含0.5-25mg(以式I化合物重量计)的式I化合物或其可药用盐作为单一活性剂。
在一些实施方案中，所述药物组合物包含式I化合物或其可药用盐，还含有药学上可接受的辅料。
在一些实施方案中，本申请提供了治疗TRK激酶介导的肿瘤的方法，其包括向受试者(例如灵长类动物、优选人)每日施用0.5-25mg的式I化合物或其可药用盐、或其药物组合物(以式I化合物重量计)。
在一些实施方案中，本申请还提供了用于治疗TRK激酶介导的肿瘤的试剂盒，其中包含：含有式I化合物或其可药用盐作为活性成分的药物组合物；任选地，还包含式I化合物或其可药用盐的药物组合物的使用说明。在一些实施方案中，所述药物组合物为包含0.5-25mg的式I化合物或其可药用盐(以式I化合物重量计)作为活性成分的单剂量药物组合物。
在一些实施方案中，本申请提供的治疗肿瘤的方法包括：
1)将对象中的肿瘤鉴定为由TRK激酶介导的肿瘤；以及
2)给予所鉴定的对象治疗有效量的式I化合物或其可药用盐、或其药物组合物。
在一些实施方案中，所述对象为灵长类动物、优选人。
在一些实施方案中，所述肿瘤由TRKA、和/或TRKB、和/或TRKC介导。
在一些实施方案中，所述肿瘤由野生型(非突变型)或者突变型的TRK介导。在一些实施方案中，所述肿瘤由野生型(非突变型)或者突变型的TRKA、和/或TRKB、和/或TRKC介导。
在一些实施方案中，所述肿瘤由包含G667C的突变型TRK介导。在一些实施方案中，所述肿瘤由包含G667C的突变型TRKA、和/或TRKB、和/或TRKC介导。
在一些实施方案中，所述突变型选自TRKA G667C。
在一些实施方案中，所述肿瘤选自具有NTRK融合基因的肿瘤。在一些实施方案中，所述肿瘤选自具有非突变型或突变型NTRK融合基因的肿瘤。在一些实施方案中，所述NTRK融合基因选自非突变型或突变型的NTRK1融合基因、和/或NTRK2融合基因、和/或NTRK3融合基因。在一些实施方案中，所述NTRK融合基因选自非突变型的NTRK1融合基因、和/或NTRK2融合基因、和/或NTRK3融合基因。在一些实施方案中，所述NTRK融合基因选自NTRK1融合基因、NTRK2融合基因、NTRK3融合基因或者G667C突变型的NTRK1融合基因。在一些实施方案中，所述NTRK融合基因可以是TPM3-NTRK1、和/或ETV6-NTRK3和/或LMNA-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是ETV6-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是LMNA-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是TPM3-NTRK1融合基因。
在一些实施方案中，所述肿瘤选自具有TRK融合蛋白的肿瘤。在一些实施方案中，所述TRK激酶介导的肿瘤选自具有非突变型或突变型TRK融合蛋白的肿瘤。在一些实施方案中，所述TRK激酶介导的肿瘤选自具有非突变型TRK融合蛋白的肿瘤。在一些实施方案中，所述TRK融合蛋白选自非突变型或突变型的TRKA融合蛋白、和/或TRKB融合蛋白、和/或TRKC融合蛋白。在一些实施方案中，所述TRK融合蛋白选自非突变型TRKA融合蛋白、和/或TRKB融合蛋白、和/或TRKC融合蛋白。在一些实施方案中，所述TRK融合蛋白选自TRKA融合蛋白、TRKB融合蛋白、TRKC融合蛋白或者G667C突变型TRKA融合蛋白。
在一些实施方案中，本申请提供的治疗肿瘤的方法包括：
1)对从受试者获得的肿瘤样品进行测定，以确定受试者是否具有NTRK融合基因或/和TRK融合蛋白；以及
2)向具有NTRK融合基因或/和TRK融合蛋白的受试者施用治疗有效量的式I化合物或其可药用盐、或其药物组合物。
在一些实施方式中，所述NTRK融合基因选自非突变型或突变型NTRK融合基因。在一些实施方式中，所述NTRK融合基因选自非突变型NTRK融合基因。在一些实施方式中，所述NTRK融合基因选自NTRK1融合基因、NTRK2融合基因、和/或NTRK3融合基因。在一些实施方式中，所述NTRK融合基因选自非突变型的NTRK1融合基因、NTRK2融合基因、和/或NTRK3融合基因。
在一些实施方案中，所述NTRK融合基因可以是TPM3-NTRK1、和/或ETV6-NTRK3、和/或LMNA-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是ETV6-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是LMNA-NTRK3融合基因。在一些实施方案中，所述NTRK融合基因可以是TPM3-NTRK1融合基因。
在一些实施方式中，所述突变型NTRK融合基因选自NTRK1 G667C。
在一些实施方式中，所述TRK融合蛋白选自野生型(即非突变型)或突变型TRK融合蛋白。在一些实施方式中，所述TRK融合蛋白选自TRKA融合蛋白、TRKB融合蛋白、和/或TRKC融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK基因可表达TRK融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK基因可表达野生型(即非突变型)或突变型TRK融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK1融合基因可表达TRKA融合蛋白。
在一些实施方案中，所述肿瘤中，G667C突变型的NTRK1融合基因可表达G667C突变型的TRKA融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK2融合基因可表达TRKB融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK3融合基因可表达TRKC融合蛋白。
在一些实施方案中，所述肿瘤中，NTRK1融合基因可表达TRKA融合蛋白；G667C突变型的NTRK1融合基因可表达G667C突变型的TRKA融合蛋白；和/或NTRK2融合基因可表达TRKB融合蛋白；和/或NTRK3融合基因可表达TRKC融合蛋白。
在一些实施方案中，本申请所述的融合基因可含有NTRK基因点突变或不含有NTRK基因点突变。在一些实施方案中，本申请所述的融合基因可含有NTRK基因点突变。在一些实施方案中，本申请所述的融合基因可不含有NTRK基因点突变。
在一些实施方案中，本申请所述的肿瘤可来自携带NTRK1、NTRK2或NTRK3基因融合且不含NTRK基因点突变的患者。
在一些实施方案中，本申请所述的肿瘤可来自既往接受TRK抑制剂治疗的患者。
在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用0.0001到20mg/kg重量(以式I化合物重量计算)。
在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用0.5-25mg或5-25mg(以式I化合物重量计算)。在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用0.5-20mg(以式I化合物重量计算)。在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用0.5-15mg(以式I化合物重量计算)。在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用0.5-10mg(以式I化合物重量计算)。在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物每次施用5-10mg(以式I化合物重量计算)。
在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自0.5-25mg或5-25mg。在一些方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自0.5mg、或1mg、或2mg、或3mg、或4mg、或5mg、或6mg、或7mg、 或8mg、或9mg、或10mg、或11mg、或12mg、或13mg、或14mg、或15mg、或16mg、或17mg、或18mg、或19mg、或20mg、或21mg、或22mg、或23mg、或24mg、或25mg，或上述任意值形成的范围。在一些方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自0.5mg-20mg。在一些方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自0.5mg-15mg。在一些方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自0.5mg-10mg。在一些方案中，所述式I化合物或其可药用盐、或其药物组合物的每日剂量(以式I化合物重量计)选自5mg-10mg。
在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物的给药频率可以是每日3次、每日2次、每日1次、每两日1次、每三日1次、每四日1次、每五天1次、每六天1次、每一周3次、每一周2次、每一周1次、每两周1次、或每三周1次。在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物的给药频率可以是每日1次。
在一些实施方案中，所述给予式I化合物或其可药用盐、或其药物组合物的给药周期是1-6个周期。在一些实施方案中，所述给予式I化合物或其可药用盐、或其药物组合物的给药周期是1、2、3、4、5、6个周期或上述任意值形成的范围。在一些实施方案中，以15-32天为1个给药周期，例如，以15-28天、15-21天、21-28天、21-32天、28-32天、15天、16天、17天、18天、19天、20天、21天、22天、23天、24天、25天、26天、27天、28天、29天、30天、31天、或32天为1个给药周期。在一些实施方案中，以28天或32天为1个给药周期。在一些实施方案中，以28-32天为1个给药周期。
在一些实施方案中，向受试者施用有效量的本申请的式I化合物或其可药用盐、或其药物组合物为连续施用。
在一些实施方案中，所述式I化合物或其可药用盐、或其药物组合物以单剂量或多剂量形式给药。
在一些实施方案中，所述受试者选自经病理和/或细胞学明确诊断的晚期恶性实体肿瘤受试者，和/或缺乏常规的有效治疗方法或常规方法治疗后失败或复发的受试者。
在一些实施方案中，所述受试者选自既往未接受TRK抑制剂治疗的受试者。
在一些实施方案中，本申请提供的方法包括在施用式I化合物或其可药用盐、或其药物组合物之前进行形态学诊断、或分子测试，或两者的组合。
在一些实施方案中，本申请提供的方法包括对从受试者获得的肿瘤样品进行测定，以确定受试者具有NTRK基因、TRK蛋白、或其表达或水平的失调。
在一些实施方案中，本申请提供的方法包括对从受试者获得的肿瘤样品进行测定，以确定受试者具有NTRK融合基因或/和TRK融合蛋白。
在一些实施方案中，所述测定的方法选自以下方法中的一种或多种：变性梯度凝胶电泳(DGGE)、温度梯度凝胶电泳(TGGE)、温度梯度毛细管电泳、单链构象多态性测定、分子信标测定、动态杂交测定、基于PCR的测定或变性高效液相色谱。
在一些实施方案中，上述肿瘤选自实体瘤。
在一些实施方案中，上述肿瘤选自晚期恶性实体瘤。
在一些实施方案中，上述肿瘤选自成人晚期恶性实体瘤。
在一些实施方案中，上述肿瘤选自胶质瘤、中枢神经系统肿瘤、肉瘤、外周原始神经外胚层肿瘤、维尔姆斯肿瘤、肺癌、甲状腺癌、结直肠癌、唾液腺癌、胆道癌、脑癌、乳腺癌、乳腺导管癌、头颈癌、细胞癌、胰腺癌、男女生殖系统肿瘤、肾癌、胆管癌、胃癌、支气管癌、胸腔癌、神经内分泌瘤、淋巴瘤或黑色素瘤。
在一些实施方案中，上述肿瘤选自软组织肉瘤、唾液腺瘤、甲状腺癌、肺癌、黑色素瘤、结直肠癌、胃癌、间质瘤、胆管癌、乳腺癌或胰腺癌。
在一些实施方案中，所述肿瘤选自乳腺癌(例如乳腺导管癌，如浸润性乳腺导管癌)，肺癌(如肺腺癌)，甲状腺癌，或结肠癌(如结肠腺癌)。
在一些实施方案中，上述肿瘤选自腺癌或甲状腺癌。在一些实施方案中，所述腺癌选自如腺导管癌、乳腺癌(如乳腺导管癌或浸润性乳腺导管癌)、肺腺癌或结肠腺癌。在一些实施方案中，所述肿瘤选自经病理和/或细胞学明确诊断的晚期恶性实体肿瘤患者；进一步，任选地选自缺乏常规的有效治疗方法或常规方法治疗后失败或复发的肿瘤患者。
在一些实施方案中，所述肿瘤选自既往有或无治疗史的肿瘤患者。在一些实施方案中，所述肿瘤选自既往有治疗史的肿瘤患者。
在一些实施方案中，所述肿瘤选自既往接受过手术治疗、表柔比星、环磷酰胺、紫杉醇(如多西紫杉醇)、培美曲塞、铂类(如卡铂、顺铂)、安罗替尼、放射治疗或依托泊苷中一种或多种治疗的肿瘤患者。
在一些实施方案中，上述肿瘤选自导管癌、乳腺癌(如乳腺导管癌，如浸润性乳腺导管癌)、肺癌(如肺腺癌)、甲状腺癌、或结肠癌(如结肠腺癌)。
在一些实施方案中，上述肿瘤选自腺癌或甲状腺癌。在一些实施方案中，所述腺癌选自如腺导管癌、乳腺癌(如乳腺导管癌或浸润性乳腺导管癌)、肺腺癌或结肠腺癌。
在一些实施方案中，所述肿瘤选自既往接受过手术治疗、和/或表柔比星+环磷酰胺、和/或紫杉醇(如多西紫杉醇)治疗的肿瘤患者。在一些实施方案中，所述肿瘤选自既往接受过手术治疗、和/或表柔比星+环磷酰胺、和/或紫杉醇(如多西紫杉醇)治疗的乳腺癌患者。在一些实施方案中，所述肿瘤选自既往接受过手术治疗、和/或表柔比星+环磷酰胺、和/或紫杉醇(如多西紫杉醇)治疗的乳腺导管癌。在一些实施方案中，所述肿瘤选自既往接受过手术治疗、和/或表柔比星+环磷酰胺、和/或紫杉醇(如多西紫杉醇)治疗的浸润性乳腺导管癌。
在一些实施方案中，所述肿瘤来自既往接受过乳腺改良根治术(手术)；任选地，进一步接受过表柔比星+环磷酰胺治疗；任选地，进一步接受过紫杉醇(如多西紫杉醇)治疗的乳腺癌(如乳腺导管癌或浸润性乳腺导管癌)患者。
在一些实施方案中，所述肿瘤来自选自既往接受过培美曲塞+铂类(如卡铂、顺铂)、和/或培美曲塞+安罗替尼治疗的肿瘤患者。在一些实施方案中，所述肿瘤来自既往接受过培美曲塞+铂类(如卡铂、顺铂)、和/或培美曲塞+安罗替尼治疗的肺癌患者。在一些实施方案中，所述肿瘤选自来自既往接受过培美曲塞+铂类(如卡铂、顺铂)、和/或培美曲塞+安罗替尼治疗的肺腺癌患者。
在一些实施方案中，所述肿瘤来自既往接受过培美曲塞+卡铂治疗，任选地进一步接受过培美曲塞+安罗替尼治疗的肺癌(如肺腺癌)患者。
在一些实施方案中，所述肿瘤选自既往接受过手术治疗、和/或放射治疗的肿瘤患者。在一些实施方案中，所述肿瘤来自既往接受过手术治疗、和/或放射治疗的甲状腺癌患者。
在一些实施方案中，所述肿瘤来自既往接受过癌症根治术(手术)治疗的甲状腺癌患者；任选地，所述手术选自甲状腺病损切除术、功能性颈淋巴结清扫术、甲状腺全部切除术、纵隔淋巴结清扫术、筋膜成形切除术中的一种或多种。任选地，所述肿瘤来自进一步接受甲状腺放射治疗的甲状腺癌患者。
在一些实施方案中，所述肿瘤来自既往接受过依托泊苷、和/或铂类(如卡铂、顺铂)治疗的肿瘤患者。在一些实施方案中，所述肿瘤来自既往接受过依托泊苷、和/或铂类(如卡铂、顺铂)治疗的结肠癌患者。在一些实施方案中，所述肿瘤来自既往接受过依托泊苷、和/或铂类(如卡铂、顺铂)治疗的结肠腺癌患者。
在一些实施方案中，所述肿瘤来自既往接受过依托泊苷治疗，任选地，进一步接受铂类(如卡铂、顺铂)治疗的结肠癌(如结肠腺癌)患者。
式I化合物或其可药用盐、或其药物组合物
本申请式I化合物可以以其游离碱形式给药，也可以以其可药用盐、水合物和前药的形式给药，该前药可在体内转换成式I化合物的游离碱形式。
在一些实施方案中，所述式I化合物或其可药用盐的药物组合物选自固体药物组合物，优选片剂或胶囊。
在一些实施方案中，所述式I化合物或其可药用盐呈药物组合物形式，其中，以式I化合物的重量计，所述药物组合物为单剂量为0.5mg-25mg的药物组合物，优选自单剂量为0.5mg、1mg、2mg、3mg、4mg、5mg、6mg、7mg、8mg、9mg、10mg、11mg、12mg、13mg、14mg、15mg、16mg、17mg、18mg、19mg、20mg、21mg、22mg、23mg、24mg、25mg或上述任意值形成的范围的药物组合物。
在一些实施方案中，本申请的药物组合物通过口服给药。
在一些实施方案中，本申请的各药物组合物为固体药物组合物。
在一些实施方案中，本申请的固体药物组合物的制剂形式为片剂。
定义和说明
除非另有说明，本申请中所用的下列术语具有下列含义。一个特定的术语在没有特别定义的情况下不应该被认为是不确定的或不清楚的，而应该按照本领域普通的含义去理解。
对于TRKA、TRKB和TRKC，其分别由基因NTRK1、NTRK2和NTRK3编码。
术语“施用”或“给予”或“给药”表示，使用本领域技术人员已知的多种方法和递送系统中的任一种，向主体物理引入治疗剂或包含治疗剂的组合物。术语“施用”或“给予”或“给药”在本文中可互换使用。
术语“治疗”一般是指获得需要的药理和/或生理效应。该效应根据部分或完全稳定或治愈疾病和/或由于疾病产生的副作用，可以是治疗性的。本文使用的“治疗”涵盖了对患者疾病的任何治疗，包括：(a)抑制疾病的症状，即阻止其发展；或(b)缓解疾病的症状，即，导致疾病或症状退化。
术语“有效量”意指(i)治疗或预防特定疾病、病况或障碍，(ii)减轻、改善或消除特定疾病、病况或障碍的一种或多种症状，或(iii)预防或延迟本文中所述的特定疾病、病况或障碍的一种或多种症状发作的本申请化合物的用量。构成“治疗有效量”的本申请化合物的量取决于该化合物、疾病状态及其严重性、给药方式以及待被治疗的哺乳动物的年龄而改变，但可例行性地由本领域技术人员根据其自身的知识及本公开内容而确定。
术语“受试者”、“患者”或“对象”是指已成为治疗、观察或实验对象的动物，优选哺乳动物，优选灵长类动物，包括人和非人灵长类动物(如猿、猴、猩猩和黑猩猩，如食蟹猴、蜘蛛猴和猕猴，如恒河猴)，最优选人。在一些实施方式中，受试者已经历和/或表现出待治疗和/或预防的疾病或病症的至少一种症状。术语“个体”可为哺乳动物，优选灵长类动物，最优选人。
如本申请所用，所述式I化合物或其可药用盐可以通过任何适用的途径和方法给药，例如通过口服或肠胃外(例如，静脉内)给药。
术语“约”应理解为包括在平均值的三个标准偏差内或特定领域中的标准公差范围内。在某些实施方式中，约应理解为不超过0.5的变异。“约”修饰其后所有列举的值。例如，“约1、2、3”表示“约1”、“约2”、“约3”。
术语“药物组合物”是指一种或多种本申请的化合物或其药物组合或其盐与药学上可接受的辅料组成的混合物。药物组合物的目的是有利于对受试者给予本申请的化合物或其药物组合。
术语“药学上可接受的辅料”是指对有机体无明显刺激作用，而且不会损害该活性化合物的生物活性及性能的那些辅料。合适的辅料是本领域技术人员熟知的，例如碳水化合物、蜡、水溶性和/或水可膨胀的聚合物、亲水性或疏水性材料、明胶、油、溶剂、水等。
本申请的药物组合物可通过将本申请的化合物与适宜的药学上可接受的辅料组合而制备，例如可配制成固态制剂，如片剂、丸剂、胶囊剂等。
本申请的药物组合物可以采用本领域众所周知的方法制造，如常规的混合法、溶解法、制粒法、制糖衣药丸法、磨细法、乳化法、冷冻干燥法等。
术语“药学上可接受的”是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。
可以通过常规的混合、填充或压片方法来制备固体口服药物组合物。例如，可通过下述方法获得：将所述的活性化合物与固体辅料混合，任选地碾磨所得的混合物，如果需要则加入其它合适的辅料，然后将该混合物加工成颗粒，得到了片剂或胶囊或糖衣剂的核心。适合的辅料包括但不限于：粘合剂、稀释剂、崩解剂、润滑剂、助流剂、甜味剂或矫味剂等。
术语“药学上可接受的盐”或“可药用盐”是指在“药学上可接受的”的定义范围内的本申请的化合物的盐。
除非另外特别说明，否则单数术语涵盖复数术语，并且复数术语涵盖单数术语。除非另外特别说明，否则词语“一个”或“一种”意指“至少一个”或“至少一种”。除非另外说明，否则“或”的使用意指“和/或”。
在本文中，除非另有说明，否则术语“包含、包括和含有”或等同物为开放式表述，意味着除所列出的要素、组分和步骤外，还可涵盖其它未指明的要素、组分和步骤。
如本申请所用，除非另有指明，“以重量计”指以式I化合物的游离形式的重量计。
术语“单剂量”是指含有一定量药品的最小包装单元，例如一盒药有七粒胶囊，则每个胶囊为单剂量；或者每瓶注射液为单剂量。术语“多剂量”由多个单剂量组成。
为了描述和公开的目的，以引用的方式将所有的专利、专利申请和其它已确定的出版物在此明确地并入本文。这些出版物仅因为它们的公开早于本申请的申请日而提供。所有关于这些文件的日期的声明或这些文件的内容的表述是基于申请者可得的信息，并且不构成任何关于这些文件的日期或这些文件的内容的正确性的承认。而且，在任何国家，在本中对这些出版物的任何引用并不构成关于该出版物成为本领域的公知常识的一部分的认可。
在一个实施方案中，本申请的药物组合可以配制成适合于单次或多次施用的药物组合物。在一个实施方案中，本申请的药物组合可为单剂量或多剂量的药物组合物。
术语“客观缓解率(ORR)”：为肿瘤体积缩小达到预先规定值并能维持最低时限(下次影像评估时)要求的受试者比例，包含完全缓解(CR)和部分缓解(PR)的病例。
术语“疾病控制率(DCR)”：为肿瘤缩小或稳定且保持一定时间的病人的比例，包含CR、PR和疾病稳定(SD)的病例。
术语“无进展生存期(PFS)”：从首次用药开始至疾病进展(PD)或PD前死亡之间的时间；若没有出现PD或PD前死亡，以最后一次影像学评估日期作为截止日期。
术语“缓解持续时间(DOR)”：在CR或PR受试者中，肿瘤第一次评估为CR或PR至PD或PD前死亡之间的时间；若CR或PR的受试者没有出现PD或PD前死亡，以最后一次影像学评估日期作为截止日期。
术语“不良事件(Adverse Event,AE)”指受试者接受试验用药品后出现的所有不良医学事件，可以表现为症状体征、疾病或实验室检查异常，但不一定与试验用药品有因果关系。不良事件性质和严重程度的评价标准遵照美国国立癌症研究所的常见毒性反应标准(NCI-CTC AE v5.0)进行。无法根据此标准进行评估的项目，可按照以下标准评定：
轻度：对病人日常生活只有轻微影响。
中度：明显影响病人日常生活。
重度：导致病人功能障碍或严重干扰日常生活。
术语“OS”：指肿瘤病人的总生存时间。
术语“DFS”：指肿瘤病人的无病生存期。
术语“TTP”：指肿瘤病人的疾病进展时间。
技术效果
本申请的治疗方案，在治疗TRK介导的肿瘤上具有较好的疗效。本申请的式I化合物或其可药用盐、或其药物组合物至少在生存疗效评价(例如OS、中位生存期)；在肿瘤反应疗效评价(例如DFS、中位DFS、PFS、TTP、ORR、DCR、DOR)中的至少一个方面具有优异的效果。并且，本申请的式I化合物或 其可药用盐、或其药物组合物起效剂量低，患者耐受性好，副作用小，不良事件少，患者预后好。其说明本申请的式I化合物其药学上可接受的盐、或其药物组合物具有良好的药用价值。
具体实施方式
为清楚起见，进一步用实施例来阐述本申请，但是实施例并非限制本申请的范围。本申请所使用的所有试剂是市售的，无需进一步纯化即可使用。
式(I)化合物可以参考WO2018077246中实施例36公开的方法制备获得。
实施例1体外细胞实验
本实验应用SRB法，评价式I化合物对人结肠癌细胞KM12体外增殖能力的抑制作用。将细胞接种于96孔板，过夜贴壁生长后，给予0.0016-16000nM浓度的式I化合物。待作用72小时后，用SRB法检测受试药对细胞株增殖能力的抑制作用。
试验结果显示式I化合物呈浓度依赖性的抑制KM12细胞的增殖。具体数值见表1。
表1.式I化合物对肿瘤细胞活性的影响
Figure PCTCN2022110448-appb-000002
实施例2式I化合物对TRK激酶及其介导的信号转导通路的影响
本实验应用Western Blot法，检测本品对TRK融合阳性的人结肠癌细胞KM12的激酶磷酸化水平和下游信号转导通路的影响。
KM12细胞培养于含10％的胎牛血清，RPMI-1640，DMEM培养液，置于37℃、5％CO 2培养箱中培养。给予浓度(4、8、16nM)的式I化合物处理细胞24h、48h，消化收集细胞，裂解制备蛋白样本，Western Blot法检测蛋白TRK、PLCγ1、AKT和Erk表达水平。
结果显示：式I化合物作用于KM12细胞24、48h能够抑制TRK受体及其下游PLCγ1、AKT和Erk信号通路的活化，抑制其磷酸化蛋白水平。
实施例3：体内实验
SPF级雌性裸小鼠(来源：南京集萃药康生物科技有限公司)腋下注射5×10 6个人结肠癌KM12细胞。
待肿瘤生长至平均体积100mm 3左右后，将动物按瘤体积随机分组后给药。受试动物按给药容量10mL/kg灌胃给予相应浓度的式I化合物，每天1次，给药周期分别为15天和21天。
每周称重和测量肿瘤体积2次，于第16天称量体重，测量肿瘤大小后处死小鼠取瘤块称重，计算相对肿瘤体积(RTV)、相对肿瘤增殖率(T/C)和肿瘤抑制百分率(IR)，并用T-test进行统计学分析。
运用裸鼠体内移植瘤的方法考察了式I化合物对人结肠癌细胞KM12在裸小鼠体内生长的影响。
结果显示：式I化合物可剂量依赖性地抑制上述细胞移植瘤的生长，且对裸小鼠体重无明显影响。
表2.式I化合物对体内移植瘤的影响
Figure PCTCN2022110448-appb-000003
T/C：相对肿瘤增殖率；IR：肿瘤抑制百分率。
实施例4临床试验
1.试验药物
式I化合物：规格0.5mg、2.5mg、5mg和10mg，片剂。
2.入组受试者
1)经病理和/或细胞学明确诊断的晚期恶性实体肿瘤受试者，缺乏常规的有效治疗方法或常规方法治疗后失败或复发；
2)优先纳入含NTRK1、NTRK2或NTRK3基因融合的受试者；
3)年龄为18-75周岁；ECOG体力状况：0-1分；预计生存期超过3个月；
4)存在RECIST 1.1标准定义的可测量病灶；
5)主要器官功能正常；
6)需采取有效方法避孕；
7)受试者自愿加入本研究，签署知情同意书，依从性好。
3.给药方案
式I化合物片，qd，空腹条件下给药(用药后一小时内不得进食)，每次服药时间应大致相近。
4.有效性指标
指标包括ORR、DCR、PFS、DOR、SD、PR、CR等。
5.试验结果
安全性
本研究在现方案规定起始剂量情况下，主要AE为1级或2级，安全性良好，部分2级AE经过对症干预均能快速转归好转。
有效性
4例患者中，均在C1(即第一个给药周期)疗效评估达到PR及以上，患者经过正常给药后，肿瘤均很好控制。结果发现本公开的治疗方案具有临床收益。
代表性病例结果如下表：
Figure PCTCN2022110448-appb-000004
Figure PCTCN2022110448-appb-000005
注：“--”代表未获得数据。
a表示的每一个用药周期为28-32天，例如C16表示用药16个周期，每个周期28-32天。
b表示目前已经监测到的最佳疗效，靶病灶直径之和比基线水平(C0期靶病灶直径之和)减少程度。

Claims (13)

  1. 一种治疗TRK激酶介导的肿瘤的方法，其包括向受试者每日施用0.5-25mg的式I化合物或其可药用盐、或其药物组合物
    Figure PCTCN2022110448-appb-100001
  2. 式I化合物或其可药用盐、或其药物组合物在制备用于治疗TRK激酶介导的肿瘤的药物中的用途，包括向受试者每日施用0.5-25mg的式I化合物或其可药用盐、或其药物组合物，
    Figure PCTCN2022110448-appb-100002
  3. 用于治疗TRK激酶介导的肿瘤的式I化合物或其可药用盐、或其药物组合物，包括向受试者每日施用0.5-25mg的式I化合物或其可药用盐、或其药物组合物，
    Figure PCTCN2022110448-appb-100003
  4. 式I化合物或其可药用盐、或其药物组合物用于治疗TRK激酶介导的肿瘤的用途，包括向受试者每日施用0.5-25mg的式I化合物或其可药用盐、或其药物组合物，
    Figure PCTCN2022110448-appb-100004
  5. 用于治疗TRK激酶介导的肿瘤的试剂盒，其中包含：含有式I化合物或其可药用盐作为活性成分的药物组合物，优选含有0.5-25mg式I化合物或其可药用盐作为活性成分的药物组合物；任选地，还包含式I化合物或其可药用盐的药物组合物的使用说明，
    Figure PCTCN2022110448-appb-100005
  6. 一种治疗肿瘤的方法，所述方法包括：
    1)将对象或受试者中的肿瘤鉴定为由TRK激酶介导的肿瘤；以及；
    2)给予所鉴定的对象或受试者治疗有效量的式I化合物或其可药用盐、或其药物组合物，
    Figure PCTCN2022110448-appb-100006
  7. 权利要求1-6任一项所述的方法、用途、化合物或试剂盒，其中，所述肿瘤由TRKA、和/或TRKB、和/或TRKC介导；
    或者，所述肿瘤由野生型(即非突变型)或者突变型的TRKA、和/或TRKB、和/或TRKC介导或者，所述肿瘤由包含G667C的突变型TRK介导；
    任选地，所述肿瘤选自具有非突变型或突变型NTRK融合基因的肿瘤；
    任选地，所述肿瘤选自具有NTRK融合基因的肿瘤；任选地，所述NTRK融合基因可以是TPM3-NTRK1、和/或ETV6-NTRK3和/或LMNA-NTRK3；任选地，所述NTRK融合基因为TPM3-NTRK1；
    或者，所述NTRK基因选自NTRK1基因、NTRK2基因、NTRK3基因或者G667C突变型的NTRK1基因。
  8. 一种治疗肿瘤的方法，所述方法包括：
    1)对从受试者获得的肿瘤样品进行测定，以确定受试者是否具有NTRK融合基因或/和TRK融合蛋白；
    2)向具有NTRK融合基因或/和TRK融合蛋白的受试者施用治疗有效量的式I化合物或其可药用盐、或其药物组合物，
    Figure PCTCN2022110448-appb-100007
    任选地，所述NTRK融合基因选自非突变型或突变型NTRK融合基因；
    任选地，所述NTRK融合基因选自非突变型NTRK融合基因；
    任选地，所述NTRK融合基因选自突变型NTRK融合基因；
    或者，所述NTRK融合基因选自NTRK1融合基因、NTRK2融合基因、和/或NTRK3融合基因；
    任选地，所述NTRK融合基因选自TPM3-NTRK1、和/或ETV6-NTRK3和/或LMNA-NTRK3融合基因；
    任选地，所述突变型NTRK融合基因为G667C突变型NTRK融合基因；
    任选地，所述TRK融合蛋白选自非突变型或突变型TRK融合蛋白；
    或者，所述TRK融合蛋白选自TRKA融合蛋白、TRKB融合蛋白、和/或TRKC融合蛋白；
    任选地所述突变型TRK融合蛋白为G667C突变型TRK融合蛋白；
    任选地，所述融合基因包含或不包含NTRK基因点突变。
  9. 权利要求1-8任一项所述的方法、用途、化合物或试剂盒，其中式I化合物或其可药用盐、或其药物组合物的每日剂量为0.5-25mg、优选5-25mg；
    或者，每日剂量选自0.5mg、或1mg、或2mg、或3mg、或4mg、或5mg、或6mg、或7mg、或8mg、或9mg、或10mg、或11mg、或12mg、或13mg、或14mg、或15mg、或16mg、或17mg、或18mg、或19mg、或20mg、或21mg、或22mg、或23mg、或24mg、或25mg、或上述任意值形成的范围。
  10. 权利要求1-9任一项所述的方法、用途、化合物或试剂盒，其中式I化合物或其可药用盐、或其药物组合物的给药频率可以是每日3次、每日2次、每日1次、每两日1次、每三日1次、每四日1次、每五天1次、每六天1次、每一周3次、每一周2次、每一周1次、每两周1次、或每三周1次。
  11. 权利要求1-10任一项所述的方法、用途、化合物或试剂盒，其中，所述受试者或对象选自经病理和/或细胞学明确诊断的晚期恶性实体肿瘤受试者或对象，和/或缺乏常规的有效治疗方法或常规方法治疗后失败或复发的受试者或对象；其中，所述受试者或对象选自灵长类动物，优选人。
  12. 权利要求1-11任一项所述的方法、用途、化合物或试剂盒，其中，所述肿瘤选自实体瘤；
    或者，所述肿瘤选自晚期恶性实体瘤；
    或者，所述肿瘤选自成人晚期恶性实体瘤；
    或者，所述肿瘤选自胶质瘤、中枢神经系统肿瘤、肉瘤、外周原始神经外胚层肿瘤、维尔姆斯肿瘤、肺癌、甲状腺癌、结直肠癌、唾液腺癌、胆道癌、脑癌、乳腺癌、乳腺导管癌、头颈癌、细胞癌、胰腺癌、男女生殖系统肿瘤、肾癌、胆管癌、胃癌、支气管癌、胸腔癌、神经内分泌瘤、淋巴瘤或黑色素瘤；
    或者，所述肿瘤选自软组织肉瘤、唾液腺瘤、甲状腺癌、肺癌、黑色素瘤、结直肠癌、胃癌、间质瘤、胆管癌、乳腺癌或胰腺癌；
    或者，所述肿瘤选自选自腺癌或甲状腺癌；任选地，所述腺癌选自腺导管癌、乳腺癌、肺腺癌或结肠腺癌，优选地，所述腺导管癌或乳腺癌为浸润性乳腺导管癌。
  13. 权利要求1-11任一项所述的方法、用途、化合物或试剂盒，其中，所述肿瘤选自导管癌、肺癌、甲状腺癌或结肠癌；
    任选地，所述肿瘤选自乳腺导管癌；
    任选地，所述肿瘤或乳腺导管癌选自浸润性乳腺导管癌；
    任选地，所述肿瘤选自肺癌；
    任选地，所述肿瘤或肺癌选自肺腺癌；
    任选地，所述肿瘤或结肠癌选自结肠腺癌。
PCT/CN2022/110448 2021-08-06 2022-08-05 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途 WO2023011616A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280046318.6A CN117597129A (zh) 2021-08-06 2022-08-05 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110900355 2021-08-06
CN202110900355.6 2021-08-06

Publications (1)

Publication Number Publication Date
WO2023011616A1 true WO2023011616A1 (zh) 2023-02-09

Family

ID=85155325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/110448 WO2023011616A1 (zh) 2021-08-06 2022-08-05 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途

Country Status (2)

Country Link
CN (1) CN117597129A (zh)
WO (1) WO2023011616A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995172A (zh) * 2013-02-19 2015-10-21 小野药品工业株式会社 Trk抑制化合物
WO2018077246A1 (zh) * 2016-10-28 2018-05-03 正大天晴药业集团股份有限公司 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
CN110028507A (zh) * 2019-01-10 2019-07-19 北京鑫开元医药科技有限公司 具有trk激酶抑制活性化合物、制备方法、组合物及用途
CN110294761A (zh) * 2018-06-08 2019-10-01 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2020078362A1 (zh) * 2018-10-15 2020-04-23 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
WO2020098720A1 (zh) * 2018-11-13 2020-05-22 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN111848626A (zh) * 2019-04-30 2020-10-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995172A (zh) * 2013-02-19 2015-10-21 小野药品工业株式会社 Trk抑制化合物
WO2018077246A1 (zh) * 2016-10-28 2018-05-03 正大天晴药业集团股份有限公司 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
CN110294761A (zh) * 2018-06-08 2019-10-01 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2020078362A1 (zh) * 2018-10-15 2020-04-23 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
WO2020098720A1 (zh) * 2018-11-13 2020-05-22 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN110028507A (zh) * 2019-01-10 2019-07-19 北京鑫开元医药科技有限公司 具有trk激酶抑制活性化合物、制备方法、组合物及用途
CN111848626A (zh) * 2019-04-30 2020-10-30 江苏柯菲平医药股份有限公司 Trk激酶抑制剂及其用途

Also Published As

Publication number Publication date
CN117597129A (zh) 2024-02-23

Similar Documents

Publication Publication Date Title
Hamaguchi et al. A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients
CN110494166A (zh) 组合疗法
JP2021506765A (ja) Ｄｕｘ４の発現に関連する疾患の治療のための化合物
BR112021005518A2 (pt) métodos para tratar distúrbios mieloproliferativos
CN110652514A (zh) 第三代egfr抑制剂的制药用途
CN115429805A (zh) 一种抗flt3-itd耐药突变型急性髓系白血病药物
WO2023092943A1 (zh) 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用
TWI835050B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
Yin et al. Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
AU2014268690A1 (en) Specific cancer treatment regimens with ganetespib
Jia et al. Shikonin Attenuates Chronic Cerebral Hypoperfusion‐Induced Cognitive Impairment by Inhibiting Apoptosis via PTEN/Akt/CREB/BDNF Signaling
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
EA021951B1 (ru) Противораковая комбинация
WO2023011616A1 (zh) 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN111686111B (zh) Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用
WO2023025141A1 (zh) 含有氨基的大环化合物在治疗trk激酶介导的肿瘤中的用途
WO2021190546A1 (zh) 包含蛋白激酶抑制剂和化疗药物的药物组合物及其用途
CN114569728A (zh) 一种组合物及其应用和药物
CN105916515A (zh) 药物组合
JP7511741B2 (ja) ２，３，５－置換されたチオフェン化合物の胃腸管間質腫瘍の予防、改善または治療用途
Chen et al. Targeted Cancer Therapies, from Small Molecules to Antibodies
CN116726182A (zh) 西奥罗尼联合抗代谢化疗药物治疗乳腺癌的用途
TW202332445A (zh) 西奧羅尼用於小細胞肺癌的治療
JP2024093825A (ja) 加齢に伴う学習・記憶機能低下の改善剤及びその使用
TWI607752B (zh) 含4-乙醯基-安卓奎諾-b之組合物用於製備抑制卵巢癌細胞生長之藥物的用 途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22852327

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280046318.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22852327

Country of ref document: EP

Kind code of ref document: A1